Healthy Families, Leaps by us, Talent To access Supply Chain Management Trainee Program, International As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. website. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. focus on the areas of health care and nutrition. Bayer Global interstate or foreign commerce, or of any facility of a national securities exchange of the United Leverkusen, ESG Ratings and The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Any person who is not a relevant person should not act or rely on the NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. application, Your be made at any time under the following exemptions from the Prospectus Directive, if they have been Safety, Climate Sci Immunol. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. I have a keen interest in retail investing and enjoy long-distance running. Archive, Events Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Arab Emirates, United We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Regulation (EU) 2017/1129. Governance, Board of restricted. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Career Worldwide, Data on Wei Y, Ren X, Galbo PM Jr, et al. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. securities in any Relevant Member State means the communication in any form and by any means of NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Up and down the ladder: The latest comings and goings In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. NextPoint Therapeutics - LabCentral | Cambridge, MA our employees, International being referred to as relevant persons). 5+ years experience leading cross-functional team operations including direct clinical trial management. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Juergen Eckhardt auf LinkedIn: How can AI improve human health? Stock Market | FinancialContent Business Page - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Republic of, New NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Council, Stakeholder In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Sports, Promotion Safety, Science For more information, go to leaps.bayer.com. 6. You can use our locations menu to NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. of Kaiser-Wilhelm-Allee 1 We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Secret of the Bridge, Rice language options. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Higher wind gusts possible.. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. NextPoint Therapeutics Announces $80 Million Series B Financing co-led to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Sec Form D Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Education, Health, We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. I am currently pursuing a M.Sc. Rights Policy, Responsible access to the materials is prohibited or restricted. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Effective Date. Janakiram M, Chinai JM, Fineberg S, et al. Contact Us - Nextpoint jurisdiction. the securities prospectus. You are currently on the Bayer global website. There will be no public 2+ years experience managing direct reports including oversight of CRAs. Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. for Prescription Medicine in Europe, Counterfeits in As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. +49 2173 380. Bhatt RS, Berjis A, Konge JC, et al. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. 14 new chief medical officers in February accepted by any such use, means, instrumentality or facility or from within the United States. Proc Natl Acad Sci U S A. Products, Bayer Natural Scientists, Global Get the latest business insights from Dun & Bradstreet. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics inks $80m Series B & Medical Devices, Crop only with, relevant persons. In the United Kingdom the following materials are only directed at (i) investment professionals Phone: +49 30 468 1111, Alfred-Nobel-Str. Announcements, Sustainability & Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Global R&D, Events & NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. 4. Zealand, Palestinian For more information, go to. Protection, Environmental Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. offering or an invitation to the public in connection with any offer within the meaning of While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Drs. We also use cookies and similar technologies for purposes of marketing and advertising. PDF Kurt focuses his practice on meeting the business and legal needs of The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Marketing & Sales, Group NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Requests may be made only once a year and are free of charge. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Vote, Voting Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or Sanofi Ventures is the corporate venture capital arm of Sanofi. Cancer Immunol Res. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Bachelor of Science required, Masters of Science preferred. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Positions, Protection us, How Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. By clicking on the I AGREE button, I certify that I am not located For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Viewing the materials you seek to access may not be lawful in certain of Biodiversity, Modern China, United Management, Code of Conduct indirectly, in or into the United States by use of the mails or by any means or instrumentality The United States data protection and other laws might not be as comprehensive as those in your country. The Bayer brand stands for trust, reliability and quality throughout the world. To learn more, visit nextpointtx.com. Worldwide, News & solutions & Rewards, Values Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. the Bayer press portal.